Teva issues about $4.9B in notes; shifts ADS to NYSE
Teva Pharmaceutical Industries is refinancing debt with roughly $4.9B/€1.5B in notes and converting its ADS into ordinary shares for NYSE trading.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is reshaping its capital structure and market profile, issuing about $4.9B/€1.5B in notes to refinance debt while shifting ADS to ordinary shares for NYSE trading. The company also cited strong commercial momentum from AUSTEDO, AJOVY and UZEDY, biosimilar expansion and positiv…